Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Current immunotherapies targeting PD-1, PD-L1, and CTLA-4 show limited efficacy in many cancer patients.
• Identifying novel immune checkpoint pathways is crucial for advancing cancer immunotherapy.
• Nectin and nectin-like molecules are implicated in regulating T- and NK-cell functions in tumors.

Purpose of the Study:

• To review the rationale for targeting TIGIT, CD226, CD96, and CD112R in cancer immunotherapy.
• To discuss the role of these receptors in regulating T- and NK-cell functions.
• To explore the potential applications of targeting these novel immune checkpoints in solid tumors.

Main Methods:

• Review of existing literature on TIGIT, CD226, CD96, and CD112R.
• Analysis of their interactions with nectin and nectin-like molecules.
• Examination of their signaling pathways in immune cells.

Main Results:

• TIGIT, CD226, CD96, and CD112R are immunoglobulin superfamily receptors interacting with nectin family molecules.
• These receptors transmit activating or inhibitory signals, modulating T- and NK-cell functions.
• Clinical trials are investigating anti-TIGIT and anti-CD112R therapies for solid tumors.

Conclusions:

• Targeting TIGIT, CD226, CD96, and CD112R represents a promising strategy for novel cancer immunotherapies.
• Further research is needed to fully elucidate the complex functions of these receptor networks.
• These pathways hold potential for overcoming resistance to existing immunotherapies.